Relationship between adhesion molecules and virological response to pegylated interferon-alpha-2a treatment in patients with chronic hepatitis B: A pilot study.
We performed a clinical study to investigate potential association between serum levels of soluble adhesion molecules and virological response to pegylated interferon-alpha-2a (PEG IFN-α-2a) treatment in patients with chronic hepatitis B (CHB). Thirty-two patients with chronic hepatitis B virus genotype B were recruited in this study, who were treated with PEG IFN-α-2a 180 μg every week and then followed up for 24 weeks. Thirty healthy control subjects were recruited from volunteer blood donors. Serum concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), soluble L-selectin (sL-selectin) in patients were investigated by enzyme-linked immunoassay before and after treatment. Serum concentrations of sICAM-1, sVCAM-1, sE-selectin and sL-selectin in CHB patients were significantly higher compared to the control group before treatment (P < 0.00001, respectively). In CHB patients responding to the PEG IFN-α-2a treatment, serum levels of sICAM-1, sVCAM-1, sE-selectin and sL-selectin were higher than those in non-responders before treatment (PI = 0.001, PV = 0.002, PE = 0.02, PL = 0.004). The levels of sICAM-1, sVCAM-1, sE-selectin and sL-selectin decreased in virological responders of treatment at 12 and 24 weeks (PI = 0.0001, PV = 0.00004, PE = 0.002, PL = 0.0004; PI = 0.00007, PV = 0.00001, PE = 0.0003, PL = 0.00003), while no obvious changes were observed in non-responders (P > 0.05, respectively). Results obtained indicated increased levels of sICAM-1, sVCAM-1, sE-selectin and sL-selectin could be related to virological response to PEG IFN-α-2a treatment in CHB patients, and have a prognostic effect on virological response.